MS Biomarker Detection via Mass Spectrometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for multiple sclerosis (MS) are challenging due to the disease's variable progression and unpredictable symptoms, making early and accurate diagnosis difficult, especially in distinguishing MS from other conditions, and existing methods often require extensive time and multiple tests.
Innovation Solution
The use of high-resolution mass spectrometry to identify specific biomarkers in cerebrospinal fluid (CSF) samples, such as Neural epidermal growth factor like 2/cerebral protein-12, Cerebellin-1, Nogo receptor, Dickkopf-3, Brevican, Chitinase-3-like 1 protein, and Neogenin, to differentiate between first-attack MS and relapsing remitting MS, allowing for earlier and more accurate diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods (MRI, CSF examination, evoked response testing) are used for multiple sclerosis diagnosis, then diagnostic accuracy can be improved, but the time required for diagnosis increases and the complexity of the diagnostic process increases
Solution Approach 1:
The patent segments the diagnostic process by identifying and measuring specific biomarker proteins (such as Nogo receptor, Cerebellin-1, and other gray matter-associated proteins) in CSF samples. This segmentation allows the complex diagnostic challenge to be broken down into measurable molecular components, enabling faster and more accurate diagnosis without requiring extensive clinical testing.
Solution Approach 2:
The patent replaces traditional mechanical and clinical diagnostic methods (MRI imaging, physical examinations, evoked response testing) with a molecular biology-based approach using mass spectrometry to detect specific protein biomarkers. This substitution transforms the diagnostic system from one relying on time-consuming clinical procedures to one based on rapid molecular analysis.
2Measurement precision
If traditional diagnostic methods are used for multiple sclerosis diagnosis, then diagnostic accuracy can be improved, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent extracts specific biomarker proteins from the complex CSF proteome that are uniquely associated with gray matter involvement in multiple sclerosis. By focusing on a targeted set of biomarkers (such as Nogo receptor, Cerebellin-1, Contactin-2) rather than analyzing the entire proteome or relying on non-specific markers, the diagnostic process becomes simpler while maintaining high accuracy.
Solution Approach 2:
The patent changes the diagnostic parameters from measuring clinical symptoms, imaging findings, or general CSF composition to measuring specific protein concentration levels and expression patterns. This parameter change transforms the diagnostic approach into a quantitative molecular assay that is both simpler to execute and more accurate in distinguishing MS from other conditions.
3Reliability
If traditional diagnostic methods are used, then differentiation between MS and other conditions can be achieved, but the time required for differential diagnosis increases
Solution Approach 1:
The patent performs preliminary identification of specific gray matter-associated biomarkers in the CSF sample that can predict MS diagnosis before other extensive testing is completed. By measuring these biomarkers early in the diagnostic workflow, the system can rapidly differentiate MS from other conditions and guide subsequent testing, reducing overall diagnostic time while maintaining reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides objective molecular evidence of gray matter involvement in early MS, enabling faster and more precise diagnosis, potentially reducing the duration and severity of the disease by facilitating timely treatment.
Implementation Method 1
high-resolution mass spectrometry to identify specific biomarkers in cerebrospinal fluid (CSF) samples
Data Source
AI summary
Biomarkers and uses thereof, as well as methods for using same for diagnosing first-attack multiple sclerosis are described herein.